Skip to content

A Clinical Study of SHR8554 Injection for the Treatment of Pain After Abdominal Surgery.

A Phase III, Randomized, Double-Blind, Placebo- and Active-controlled Study of SHR8554 Injection for the Treatment of Pain After Abdominal Surgery.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04766463
Enrollment
528
Registered
2021-02-23
Start date
2021-03-03
Completion date
2021-11-01
Last updated
2022-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

The primary objective is to evaluate the analgesic efficacy of IV SHR8554 compared with placebo and morphine in patients with acute postoperative pain following abdominal surgery

Interventions

SHR8554 Injection; high dose

DRUGPlacebo

Saline Solution

DRUGMorphine

Morphine

Sponsors

Jiangsu HengRui Medicine Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

Parallel Assignment

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Able and willing to provide a written informed consent 2. Subjects requiring elective general anesthesia abdominal surgery 3. Conform to the ASA Physical Status Classification

Exclusion criteria

1. Subjects with a history of difficult airway 2. Subjects with a history of reflux esophagitis 3. Subjects with a history of mental illness 4. Subjects with poor blood pressure control 5. Transcutaneous oxygen saturation (SpO2) \<90% 6. Random blood glucose ≥11.1mmol/L 7. Subjects with abnormal liver function 8. allergies to opioids and other medications that may be used during the trial 9. Pregnant or nursing women

Design outcomes

Primary

MeasureTime frameDescription
the Sum of Pain Intensity Differences in Pain Score Over 24 Hours24-hoursPain intensity will be evaluated using an 11-point (0-10) Numeric Pain Rating Scale (NPRS), with higher numbers indicating a higher pain intensity, administered over 24 hours. Time weighted average change from baseline is calculated using the following: time weighted sum of pain intensity differences (SPID) divided by a constant (24 hours) to yield values on the 0-10 NPRS.

Secondary

MeasureTime frameDescription
the Sum of Pain Intensity Differences in Pain Score Over 6、12、18 、12-18 Hours6-hours、12-hours、18-hours、12-18 hourstime weighted sum of pain intensity differences (SPID) divided by a constant (6、12、18 、12-18 hours) to yield values on the 0-10 NPRS.
Time of first use of remedial analgesic medication24-hoursThe first time to use parecoxib sodium for injection
Cumulative use of remedial analgesics from 0h to 24h24-hoursCumulative use of parecoxib sodium for injection / sufentanil hydrochloride injection
Participant ' satisfaction score for analgesia treatment24-hoursParticipants recalled the postoperative analgesia effect and rated their satisfaction on a scale of 0 to 10, with 0 representing dissatisfied and 10 representing very satisfied.
Investigator satisfaction score for analgesia treatment24-hoursPostoperative analgesia was evaluated by investigators.The scale ranges from 0 to 10, with 0 being dissatisfied and 10 being very satisfied.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026